Oxford BioMedica says new data presented from two clinical studies indicate “ground-breaking” long-term sustained and dose-dependent gene expression with its LentiVector gene therapy delivery platform.
News
Biogen to spin off haemophilia business
Biogen is intending to spin off its haemophilia business as an independent, publicly traded company, in a move designed to enable each business to better focus on driving value in their respective areas of expertise.
Amgen’s Blincyto gets speedy US review for paediatric patients
New immunotherapy for ALL
Regeneron unveils encouraging data for osteoarthritis pain drug
Regeneron has unveiled encouraging top-line data from a placebo-controlled Phase II/III study assessing its investigational Nerve Growth Factor antibody fasinumab in patients with moderate-to-severe uncontrolled osteoarthritis pain of the hip or knee.
AZ completes deal for Takeda’s respiratory unit
AstraZeneca has completed its acquisition of Takeda’s core respiratory business, in a move which the drug giant says will be accretive to its 2016 earnings.
FDA green lights first Parkinson’s psychosis drug
US regulators have issued a green light for Acadia Pharmaceuticals’ atypical antipsychotic Nuplazid, offering patients the potential to access the first treatment for Parkinson’s disease psychosis (PDP).
CHMP recommends EU approval for six new medicines
Six new medicines, including a new antibacterial and therapies for multiple sclerosis and Parkinson’s disease, have jumped closer to European approval, after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
J&J loses another talc-cancer case; fined $55m
Johnson & Johnson has lost another US lawsuit alleging that the firm knew of increased cancer risks from regular use of its talc-based products but failed to warn consumers, potentially paving the way for thousands more similar cases.
Abbott to spend $25bn on St Jude Medical
Abbott is buying medical device maker St Jude Medical in a deal worth around $25 billion.
NICE recommends Novartis skin cancer combo for NHS use
The National Institute for Health and Care Excellence is recommending NHS use of Novartis’ oral combination therapy Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
Apple launches CareKit platform with four apps
Apple has now launched its new CareKit platform with four active apps on offer targeting management of diabetes, depression, and maternal/baby health.
AbbVie boosts oncology portfolio with Stemcentrx buy
AbbVie has announced plans to snap up privately held US cancer drugmaker Stemcentrx in a deal potentially worth $9.8 billion, in a move designed to expand its solid tumour development pipeline.
Cuts Survival Pack’ sent to pharmacists in England
Pharmaceutical wholesaler Mawdsleys is sending out a ‘Cuts Survival Pack’ to pharmacists in England to help them deal with the impact of looming government funding cuts.
Sanofi offers $9.3 billion for Medivation
French drugmaker Sanofi has swooped in with a $9.3 billion-bid for US biopharma Medivation, in an attempt to secure access to prostate cancer drug Xtandi and further bulk up its oncology offering.
Servier’s Lonsurf approved in Europe for colorectal cancer
Servier’s Lonsurf has been cleared for use in Europe to treat certain patients with metastatic colorectal cancer.
